Abstract
Background
Consumption of hydrogen-rich water (HRW) has been shown to have anti-inflammatory and metabolic-modulatory benefits.
Objective
A randomized, placebo-controlled trial was conducted to assess the potential blood uric acid-lowering effects of HRW consumption with different doses (low and high doses) and duration (4 and 8 weeks) in patients with hyperuricemia.
Methods
The Placebo group consumed three bottles of ordinary drinking water (330 mL per bottle), the Low-HRW group consumed two bottles of HRW (330 mL per bottle, H2 ≥ 4.66 mg/L) and a bottle of ordinary water, and the High-HRW group consumed three bottles of HRW daily for 8 weeks. The primary outcome was the blood uric acid levels following different time points (4 and 8 weeks) compared to baseline.
Results
A total of 100 participants completed the entire trial (32 in Placebo, 35 in Low-HRW, and 33 in High-HRW groups). The high-dose of HRW was more effective than low-dose HRW in controlling blood uric acid. Following an 8-week period, the High-HRW group exhibited a significant reduction in blood uric acid levels compared to the baseline (488.2 ± 54.1 μmol/L to 446.8 ± 57.1 μmol/L, P < 0.05).
Conclusion
As a rather safe agent, the prolonged consumption of HRW may be feasible in the management of hyperuricemia.
Clinical trial registration
chictr.org.cn, identifier ChiCTR2200066369.
Keywords: Blood uric acid, Hyperuricemia, Hydrogen-rich water, Dose-effect, Time-effect
1. Introduction
Hyperuricemia, a metabolic disorder resulting from impaired purine metabolism, exhibits a higher incidence among middle-aged and elderly males, as well as postmenopausal females. In China, the prevalence of hyperuricemia among adults is estimated to be 14.0 %, including 24.4 % in males and 3.6 % in females, and it continues to increase annually [1,2].
Lifestyle modifications, such as adopting a healthy diet, limiting alcohol consumption, and engaging in regular exercise, have been empirically demonstrated to be efficacious in the prevention and management of hyperuricemia [3,4]. However, when lifestyle modifications cannot achieve the expected effect, specific medications become necessary.
The existing drugs for the treatment of hyperuricemia include uricostatic agents (allopurinol and febuxostat), uricosuric agents (probenecid, benzbromarone, and losartan), and uricolytic agents (plegoticase and rasburicase) [5]. Nevertheless, the majority of these drugs intended to reduce uric acid level are associated with adverse effects, including increased risks of gastrointestinal disorders, cardiovascular diseases, hepatic impairment, and renal dysfunction [5,6]. For instance, allopurinol is a widely used drug of reducing uric acid level, but the occurrence of allopurinol-induced severe cutaneous adverse drug reactions has been reported to range from 3 to 4.68 cases per 1000 new users [6,7]. Consequently, it is imperative to explore a safe and effective supplementary treatment to assist patients in reducing uric acid level while mitigating adverse effects.
Multiple studies have demonstrated a close association between hyperuricemia and oxidative damage caused by reactive oxygen species, and there was a strong correlation between inflammation and uric acid levels across the entire spectrum from hyperuricemia to gout [8,9]. Meanwhile, hyperuricemia has been associated with various diseases including acute and chronic nephropathy, obesity, metabolic syndrome, diabetes, cardiovascular diseases, and hypertension [[10], [11], [12]].
Molecular hydrogen (H2) has been proven to be an anti-oxidative and anti-inflammatory agent [[13], [14], [15]]. Clinical studies have demonstrated that H2 could play a role in the management of obesity, diabetes, cardiovascular diseases, etc [[16], [17], [18], [19], [20]]. These findings imply the potential utility of H2 in the treatment of hyperuricemia.
There are various routes for H2 administration such as H2-rich water (HRW) drinking, H2 gas inhalation, and H2 water bath [21,22]. HRW refers to regular water that contains dissolved H2, and HRW drinking is convenient and extremely bio-safe. A previous randomized placebo-controlled clinical study revealed that a 3-month HRW drinking could exhibit therapeutic benefits in male patients with hyperuricemia [23]. However, the time-effect and dose-effect of HRW are still required for enhanced clinical efficacy.
In this study, we conducted a randomized, placebo-controlled trial to assess the effectiveness of various doses and durations of HRW consumption on patients with hyperuricemia.
2. Materials and methods
2.1. Study design
This study consisted of an 8-week randomized, placebo-controlled, parallel-design trial conducted from May to July 2023. After obtaining informed consent, all participants were randomly allocated to the Placebo group, the Low-HRW group, or the High-HRW group. The intervention was single-blind. The study followed the recommendations of the Consolidated Standards of Reporting Trials (CONSORT) statement for reporting randomized controlled trials. Written informed consent was obtained from all participants. The trial was approved by the Ethical Committee of the Second Affiliated Hospital of Shandong First Medical University (No.2022-122) and was registered at the Chinese Clinical Trial Registry (chictr.org.cn) with the registration number ChiCTR2200066369 (registered on: December 2, 2022). All procedures were carried out in accordance with the Helsinki Declaration.
2.2. Participants
Participants were recruited from Longkou City, Shandong, China. Adult participants with baseline blood uric acid levels >420 μmol/L for males and >360 μmol/L for females were enrolled [24,25]. Exclusion criteria included individuals taking medications that could potentially decrease uric acid levels, those with gout arthritis, with a medical history of severe conditions such as heart failure, malignant tumors, or organ transplant, as well as women during pregnancy or lactating. The criteria for discontinuation encompassed withdrawal of consent, non-compliance, or other medical factors that required the termination of the intervention. Randomized control assignment was performed by an investigator utilizing the R program (1: 1: 1). Each number was placed in a separate, opaque envelope kept by the investigator; each envelope contained the treatment allocation card (experimental group or placebo group). All the investigators knew the assignment and the intervention plan, but the participants did not.
2.3. Intervention
Participants of the Placebo group were instructed to consume three bottles of placebo water (ordinary drinking water with the same appearance as HRW, 330 mL per bottle) daily. The Low-HRW group consumed two bottles of HRW (330 mL per bottle) and one bottle of placebo water daily. The High-HRW group consumed three bottles of HRW daily. The HRW and placebo water are packaged in aluminum cans and supplied by the Beijing Huoliqingyuan Co., Ltd. (Beijing, China). Participants were instructed to consume one bottle of water within 10 min in the morning, noon, and evening, respectively. All participants were instructed to adhere to their regular dietary, pharmaceutical, and lifestyle practices. The H2 concentration of HRW was determined by a Clark-type H2 microsensor (Unisense, Aarhus N, Denmark) in our laboratory by the method previously reported [22], and the H2 concentration was ≥4.66 mg/L. By calculation, the daily H2 intake doses were about 3.08 mg and 4.61 mg in the Low-HRW group and High-HRW group, respectively.
2.4. Outcomes
The primary outcome of this study was the blood uric acid level, and the secondary outcomes included the proportion of participants who achieved a reduction of at least 10 % in blood uric acid after 4 and 8 weeks, as well as the plasma biochemical parameters. The blood uric acid was detected after overnight fasting in participants' fourth finger using a portable uric acid detector (Sannuo Biosensing Co., Ltd., Hunan, China) by a trained technician, and the average of two consecutive measurements was taken. Fasting venous blood samples from median cubital vein were collected into EDTA tubes and subsequently centrifuged (15 min at 1300 g) to obtain plasma. Alkaline phosphatase (ALP), aspartic aminotransferase (AST), alanine aminotransferase (ALT), β2-microglobulin (β2-MG), creatinine (Cr), blood urea nitrogen (BUN), total cholesterol (TC), HDL-cholesterol (HDL-C), LDL-cholesterol (LDL-C), and triglyceride (TG) and glucose (GLU) were analyzed by an automatic biochemical analyzer (HITACHI 7080).
2.5. Sample size estimation
The sample size was estimated using the G-Power software, with a 95 % confidence interval, a test power of 85 %, and a 15 % probable drop, and the sample size was calculated to be 114 for three groups.
2.6. Statistical analysis
The data were presented as mean and standard deviation (mean ± SD), median (Quantile 1 and Quantile 3), or percentage. The presence of skewness, outliers, and systematic missing data was evaluated. The normal distribution of the data was assessed using the Shapiro–Wilk test. The blood uric acid levels were analyzed using repeated-measures analysis of variance (ANOVA) followed by Bonferroni's test. The ANOVA, unpaired t-test, and paired t-tests were used to detect inter and intra-group differences in data that adhered to a normal distribution. For data that did not conform to a normal distribution, the Mann-Whitney U test (unpaired) and Wilcoxon signed rank test (paired) were utilized to compare differences. To determine differences between groups of categorical data (eg, proportion with underlying diseases or proportion with ≥10 % decline in blood uric acid), Pearson χ2 test or Fisher exact test were used as applicable. Statistical analyzes were performed by SPSS 26.0 (SPSS Inc., Chicago, IL, USA). P < 0.05 was considered as significantly different in statistics.
3. Results
3.1. Participants
A total of 130 participants agreed to participate in this study, and 114 participants were recruited according to the inclusion and exclusion criteria. These participants were then randomly assigned to the Placebo group (n = 38), the Low-HRW group (n = 38), or the High-HRW group (n = 38). During the follow-up, 6 participants in the Placebo group (One participant was dropped out due to scheduling conflicts and five participants concerned about personal reasons), 3 participants in the Low-HRW group (Three participants were dropped out due to personal reasons), and 5 participants in the High-HRW group (One participant was dropped out due to scheduling conflicts and four participants concerned about personal reasons) withdrew their participation. Finally, a total of 32 participants from the Placebo group, 35 participants from the Low-HRW group, and 33 participants from the High-HRW group successfully completed the 8-week follow-up study (Fig. 1). Upon analysis, it was determined that there were no significant differences in baseline characteristics among the three groups for participants who completed the trial (P > 0.05, Table 1). Furthermore, no adverse effects were reported throughout the entire duration of the study.
Fig. 1.
Trial flowchart.
Table 1.
Baseline characteristics of participants.
| Characteristics | Placebo group (n = 32) | Low-HRW group (n = 35) | High-HRW group (n = 33) | P |
|---|---|---|---|---|
| Male, No. (%) | 26 (21.25) | 30 (85.71) | 27 (81.82) | 0.867 |
| Female, No. (%) | 6 (18.75) | 5 (14.29) | 6 (18.18) | 0.867 |
| Age, years | 35.25 ± 8.08 | 34.23 ± 8.57 | 35.36 ± 8.75 | 0.831 |
| Weight, kg | 79.91 ± 16.50 | 85.23 ± 15.21 | 83.94 ± 19.78 | 0.428 |
| Body mass index | 26.72 ± 4.70 | 28.16 ± 4.57 | 27.44 ± 4.94 | 0.466 |
| SBP, mmHg | 125.78 ± 13.16 | 126.60 ± 21.89 | 128.63 ± 11.12 | 0.766 |
| DBP, mmHg | 79.98 ± 9.56 | 81.26 ± 8.88 | 79.82 ± 8.76 | 0.768 |
| Smoking, n (%) | 11 (34.38) | 11 (31.43) | 10 (30.30) | 0.955 |
| Alcohol drinking, n (%) | 8 (25.00) | 7 (20.00) | 7 (21.21) | 0.878 |
| Uric acid, μmol/L | 486.4 ± 71.1 | 484.8 ± 64.6 | 488.2 ± 54.1 | 0.975 |
| Underlying diseases | ||||
| Fatty liver, n (%) | 7 (21.88) | 5 (14.29) | 4 (12.12) | 0.531 |
| Hypertension, n (%) | 2 (6.25) | 1 (2.86) | 2 (6.06) | 0.77 |
| gout, n (%) | 0 (0) | 1 (2.86) | 1 (3.03) | 0.618 |
| Diabetes, n (%) | 0 (0) | 1 (2.86) | 1 (3.03) | 0.618 |
Age, weight, body mass index, SBP, DBP, and uric acid are presented as the mean ± SD. Intergroup differences were tested by Analysis of Variance (age, weight, body mass index, SBP, DBP, uric acid) or the Kruskall-Wallis test (sex, smoking, alcohol drinking, underlying diseases).
3.2. Blood uric acid
The blood uric acid levels were assessed prior to the intervention, as well as at 4 weeks and 8 weeks following the intervention. As shown in Fig. 2A and Table S1, there were no statistically significant differences in blood uric acid levels between the Placebo and Low-HRW groups at various time points, although a slight but not significant decrease was observed at 8 weeks in the Low-HRW group compared to baseline (P > 0.05). In contrast, the High-HRW group exhibited a tendency towards decreased blood uric acid levels at 4 weeks (P > 0.05), with a significant decrease observed at 8 weeks compared to baseline (488.2 ± 54.1 μmol/L to 446.8 ± 57.1 μmol/L, P < 0.05).
Fig. 2.
A: Blood uric acid at baseline and after 4 weeks and 8 weeks of intervention; B: Changes in blood uric acid compared to the baseline. Data are represented as the mean ± SD; *P < 0.05 compared to the Baseline.
The changes in blood uric acid levels are depicted in Fig. 2B and Table S1. After 4 weeks, the average uric acid level in the Low-HRW group exhibited minimal variation compared to the baseline, and it experienced a reduction of 6.74 μmol/L in the High-HRW group. After a period of 8 weeks, the average uric acid level decreased by 19.0 μmol/L in the Low-HRW group and 41.6 μmol/L in the High-HRW group.
We further analyzed the number and percentage of participants with over 10 % decline in blood uric acid level (Table 2). In the Low-HRW group, 7 out of 35 participants (39.4 %) and 13 out of 35 participants (37.1 %) demonstrated a ≥10 % decrease in blood uric acid levels after 4 and 8 weeks, respectively. Meanwhile, in the High-HRW group, 8 out of 33 participants (24.2 %) and 13 out of 33 participants (39.4 %) exhibited a ≥10 % decrease in blood uric acid after 4 and 8 weeks, respectively. There were no significant differences in either the Low-HRW group and the High-HRW group compared to the Placebo group or the Low-HRW group compared to the High-HRW group (P > 0.05).
Table 2.
Participants exhibiting a reduction of more than 10 % in blood uric acid levels.
| Placebo group (n = 32) | Low-HRW group (n = 35) | High-HRW group (n = 33) | Pa | Pb | Pc | |
|---|---|---|---|---|---|---|
| 4 weeks | 3 (9.38 %) | 7 (20 %) | 8 (24.2 %) | 0.38 | 0.19 | 0.77 |
| 8 weeks | 7 (21.9 %) | 13 (37.1 %) | 13 (39.4 %) | 0.19 | 0.18 | 1.00 |
Data are presented as numbers (percentages). aLow-HRW group vs. Placebo group. bHigh-HRW group vs. Placebo group. cLow-HRW group vs. High-HRW group.
3.3. Blood assays
Plasma biochemical indicators of all participants were examined before and after the trial. As shown in Table 3, for the liver function indicators, the ALP levels were significantly lower in the Low-HRW group and High-HRW group compared to the baseline after an 8-week intervention, while it displayed a significant increase in the Placebo group. However, no statistically significant differences were observed in the AST and ALT levels among the three groups (P > 0.05).
Table 3.
Plasma biochemical parameters at baseline and after the 8-week intervention.
| Placebo group (n = 32) |
Low-HRW group (n = 35) |
High-HRW group (n = 33) |
||||
|---|---|---|---|---|---|---|
| Baseline | 8 weeks | Baseline | 8 weeks | Baseline | 8 weeks | |
| ALP, U/L | 78.9 ± 16.2 | 79.2 ± 17.3* | 74.8 ± 20.4 | 71.9 ± 16.0* | 76.4 ± 16.1 | 75.7 ± 18.7* |
| AST, U/L | 19.0 (15, 31.3) | 21.0 (16.3, 28.8) | 19.0 (16.0, 24.0) | 21.0 (17.0, 25.5) | 21.0 (15.0, 30.5) | 22.0 (18.5, 31.0) |
| ALT, U/L | 29.5 (20.5, 49.3) | 29.5 (17.3, 44.8) | 30.0 (21.0, 36.0) | 29.0 (20.0, 38.0) | 26.0 (18.5, 50.0) | 27.0 (21.0, 44.0) |
| β2-MG, mg/L | 1.70 (1.58, 2.00) | 1.81 (1.63, 2.09) | 1.55 (1.33, 1.94) | 1.66 (1.36, 1.84) | 1.70 (1.44, 1.87) | 1.66 (1.40, 1.85) |
| BUN, mmol/L | 5.07 ± 0.91 | 5.29 ± 1.09* | 4.91 ± 0.95 | 5.19 ± 1.16* | 4.80 ± 0.76 | 4.90 ± 1.12* |
| Cr, μmol/L | 74.5 (66.3, 88.0) | 71.6 (63.8, 84.3) | 75.0 (67.0, 82.0) | 77.2 (72.0, 81.4) | 74.0 (65.6, 83.0) | 75.1 (66.3, 85.6) |
| TC, mmol/L | 4.37 (3.83, 5.26) | 4.44 (3.98, 5.31) | 4.56 (3.91, 5.19) | 4.50 (4.01, 4.91) | 4.55 (4.09, 5.41) | 4.65 (4.34, 5.39) |
| LDL-C, mmol/L | 2.71 (2.28, 3.34) | 2.75 (2.11, 3.15) | 2.95 (2.41, 3.30) | 2.85 (2.21, 3.11) | 2.77 (2.34, 3.31) | 2.78 (2.36, 3.18) |
| HDL-C, mmol/L | 1.09 (0.98, 1.24) | 1.02 (0.95, 1.15)* | 1.11 (0.96, 1.35) | 1.05 (0.94, 1.27)* | 1.17 (1.07, 1.37) | 1.15 (1.00, 1.30)* |
| TG, mmol/L | 1.81 (1.18, 2.81) | 1.98 (1.04, 2.43) | 1.47 (0.99, 2.26) | 1.73 (1.08, 2.64) | 1.61 (1.05, 2.19) | 1.47 (1.10, 2.43) |
| GLU, mmol/L | 5.09 (4.60, 5.45) | 5.33 (5.05, 5.60)* | 5.10 (4.79, 5.32) | 5.29 (4.99, 5.67)* | 5.06 (4.80, 5.29) | 5.24 (5.00, 5.47)* |
Data are median (Quantile 1, Quantile 3) or mean ± SD. *P < 0.05 vs. baseline in the same group by paired t-test or Wilcoxon signed rank test.
For the renal function indices, the alterations in β2-MG and Cr did not exhibit statistical significance (P > 0.05) in both the Low-HRW group and High-HRW group. Nevertheless, the levels of BUN demonstrated a significant increase in all three groups after 8 weeks compared to the baseline. The lipid-related indices, including TC, LDL-C, and TG, did not display any statistically significant differences after the 8-week intervention. However, the levels of HDL-C noticeably decreased in all three groups following the intervention. Additionally, the GLU levels exhibited a marked increase in all three groups after the intervention.
4. Discussion
In the current randomized placebo-controlled study, it was observed that an 8 weeks High-HRW intervention resulted in a significant reduction in uric acid levels compared to baseline.
H2 is acknowledged as a relatively safe agent. In the food industry, H2 has obtained official approval as a food additive due to its non-toxic properties [16,26]. A clinical trial has demonstrated that the healthy adults experienced no adverse effects when exposed to 2.4 % H2 gas through inhalation for a duration of up to 72 h [27]. Thus, H2 is well suited for use in adjuvant therapy.
HRW consumption is feasible for daily use. Compared with other H2-supply routes such as inhaling H2 gas, taking a H2-water bath, or stimulating intestinal microbiomes to produce H2, the consumption of bottled HRW ensures an accurate H2-dose. Previous clinical studies have demonstrated the potential benefits of HRW consumption in patients with type 2 diabetes [28], metabolic syndrome [29], unstable angina [17], etc. A six-month study found that the consuming of HRW reduced the level of uric acid in the plasma of healthy rats [30]. Meanwhile, a previous clinical trial assessed that the consumption of HRW could decrease the uric acid levels among individuals with hyperuricemia [23]. However, few studies have been conducted to investigate the time effect and dose effect of H2 intake. In the current study, low and high doses of HRW were employed, and the effects at different times of 4 weeks and 8 weeks were investigated.
The solubility of H2 in water is approximately 1.6 mg/L under standard conditions (20 °C, 101.325 kPa). The utilization of micro and nanobubbles technologies has been shown to enhance the solubility of H2 in water. In the previous clinical studies, the H2 concentrations in HRW varied from 0.4 to 1.6 mg/L [29,31], and it resulting in significant differences in the daily intake of H2. In our current study, the concentration of H2 in HRW was measured as 4.66 mg/L.
The optimal duration for the HRW intervention remains unexplored. For the intervention of metabolic syndrome, the duration of intervention ranging from 8 to 24 weeks [29,32,33], and HRW consuming effectively regulated plasma lipid indices. For patients with non-alcoholic fatty liver disease, HRW intervention durations ranged from 4 to 8 weeks [19,34,35]. In order to assess the intervention effect over time, the current study examined blood uric acid levels after 4 and 8 weeks of HRW consumption. The results of our trial indicate a significant reduction in uric acid levels following an 8-week high-dose HRW intervention. In contrast to pharmacological interventions., the consumption of HRW appears to require a long-term administration for the attainment of clinical efficacy. Considering its remarkable safety profile, HRW is suited as an adjuvant therapy for metabolic disorders.
Hyperuricemia, a metabolic disorder caused by elevated levels of uric acid in the bloodstream due to disrupted purine metabolism, has been found to be associated with inflammatory disorders in previous studies [8,36]. There have studies indicated that the levels of inflammatory markers, including interleukin-6 (IL-6), tumour necrosis factor-α (TNF-α) and transforming growth factor-β1 (TGF-β1), are markedly elevated in individuals with hyperuricaemia in comparison to those in a healthy state [37]. The levels of IL-6, TNF-α, and TGF-β1 may exacerbate renal tubular and interstitial damage, which may in turn lead to impaired uric acid excretion [37]. Oxidative stress plays a pivotal role in the pathogenesis, progression and regression of hyperuricaemia. Xanthine oxidoreductases (XORs) are pivotal enzymes in uric acid production [38,39]. It has been demonstrated that in humans, XORs may be implicated in the aetiology of metabolic disorders such as hyperuricaemia and metabolic syndrome through oxidative stress, XORs-derived reactive oxygen species, and uric acid-induced inflammatory responses [40,41]. Extensive basic and clinical studies have demonstrated that H2 possesses the capacity to inhibit inflammatory responses, suggesting its potential benefits in the management of hyperuricemia. The potential mechanisms involved in the antioxidant and anti-inflammatory effects of H2 have not yet been completely elucidated. Ohsawa et al. found that H2 selectively reduced hydroxyl radical in cultured cells [13]. Jin et al. proposed that ferroporphyrin may be a biological target of H2, through which hydroxyl radical is reduced into H2O [42]. The mechanisms of HRW consumption on regulating oxidative stress and inflammatory responses, and thereby reducing blood uric acid levels require further inquiry.
Studies have showed a clear relationship of increased uric acid levels with various pathological conditions such as metabolic syndrome, obesity, hypertension, and cardiovascular events [[10], [11], [12]]. Previous clinical studies indicated that consumption of HRW might exert beneficial effect on multiple metabolic diseases. A placebo-controlled trial demonstrated that supplementation with a high-concentration of HRW produced via H2-producing tablets favorably modulated fatty acid and glucose metabolism, and improved inflammation and redox homeostasis in subjects with metabolic syndrome [33]. In patients with type 2 diabetes mellitus, it is noted that supplementation with HRW decreased the levels of oxidized LDL, free fatty acids, and urinary 8-isoprostanes, and may have a beneficial role in the insulin resistance [28]. Another placebo-controlled clinical study suggested that H2 may have potentially beneficial impact on glucose metabolism by modifying the gut microbiota of individuals with impaired fasting glucose [20]. For the regulation of lipid metabolism, it is suggested that HRW have beneficial lipid-lowering effects and can improve high-density lipoprotein function in patients with hypercholesterolemia. Meanwhile, several studies have shown that the consumption of HRW could have advantageous effects on diverse biomarkers for liver function and regulate lipid levels in patients with non-alcoholic fatty liver disease [19,34,43]. The ameliorative effect of HRW on these diseases may play a positive role in the treatment of hyperuricemia.
Our study still has some limitations. Firstly, the duration was relatively short, the long-term beneficial effects of HRW warrant further investigation. Secondly, the daily dietary and physical activity of the participants were not monitored. Thirdly, more biomarkers such as oxidative stress and inflammatory indicators were not addressed in the study. Moreover, due to the limited number of female participants in our study, we were unable to examine the potential impact of HRW on gender-based differences.
5. Conclusion
In conclusion, consumption of HRW at a dose of 330 mL each time and three times daily (totally 4.61 mg H2) for 8 weeks significantly reducing the blood uric acid level in patients with hyperuricemia. It is indicated that a long-term consumption of HRW might exert a beneficial effect in the management of uric acid level.
Ethics statement
The trial was approved by the Ethical Committee of the Second Affiliated Hospital of Shandong First Medical University (No.2022-122) and was registered at the Chinese Clinical Trial Registry (chictr.org.cn) with the registration number ChiCTR2200066369 (registered on: December 2, 2022).
Data availability statement
The data that support the findings of this study are available from the corresponding author upon reasonable request.
CRediT authorship contribution statement
Fenglin Wu: Writing – original draft, Investigation, Formal analysis, Data curation. Jun Ma: Writing – original draft, Investigation, Data curation. Junli Xue: Writing – original draft, Investigation. Xue Jiang: Writing – original draft, Investigation. Jinyu Liu: Writing – original draft, Investigation. Jiashuo Zhang: Writing – original draft, Investigation. Yazhuo Xue: Writing – review & editing, Supervision, Investigation, Conceptualization. Boyan Liu: Writing – review & editing, Writing – original draft, Supervision, Investigation, Funding acquisition, Formal analysis, Conceptualization. Shucun Qin: Writing – review & editing, Investigation, Funding acquisition, Conceptualization.
Declaration of competing interest
None.
Acknowledgements
This research was funded by the National Natural Science Foundation of China [82200508, 81770855], Science and Technology Support Plan for Youth Innovation Team of Universities in Shandong Province [2023KJ184], and Academic Promotion Programme of Shandong First Medical University [2019QL010]. The authors thank Beijing Huoliqingyuan Co., Ltd. for providing H2 water.
Footnotes
Supplementary data to this article can be found online at https://doi.org/10.1016/j.heliyon.2024.e36401.
Contributor Information
Yazhuo Xue, Email: yzhxue@126.com.
Boyan Liu, Email: byliu@sdfmu.edu.cn.
Shucun Qin, Email: scqin@sdfmu.edu.cn.
Appendix A. Supplementary data
The following is the supplementary data to this article:
References
- 1.Piao W., Zhao L., Yang Y., et al. The prevalence of hyperuricemia and its correlates among adults in China: results from CNHS 2015-2017. Nutrients. 2022;14(19):4095. doi: 10.3390/nu14194095. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Zhang M., Zhu X., Wu J., et al. Prevalence of hyperuricemia among Chinese adults: findings from two nationally representative cross-sectional surveys in 2015-16 and 2018-19. Front. Immunol. 2021;12 doi: 10.3389/fimmu.2021.791983. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.FitzGerald J.D., Dalbeth N., Mikuls T., et al. American college of rheumatology guideline for the management of gout. Arthritis Care Res. 2020;72(6):744–760. doi: 10.1002/acr.24180. 2020. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.Sautner J., Eichbauer-Sturm G., Gruber J., Lunzer R., Puchner R. [2022 Update of the Austrian Society for Rheumatology and Rehabilitation nutrition and lifestyle recommendations for patients with gout and hyperuricemia] Z. Rheumatol. 2023;82(1):71–81. doi: 10.1007/s00393-022-01286-2. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Afinogenova Y., Danve A., Neogi T. Update on gout management: what is old and what is new. Curr. Opin. Rheumatol. 2022;34(2):118–124. doi: 10.1097/BOR.0000000000000861. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.Terkeltaub R. Emerging urate-lowering drugs and pharmacologic treatment strategies for gout: a narrative review. Drugs. 2023;83(16):1501–1521. doi: 10.1007/s40265-023-01944-y. [DOI] [PubMed] [Google Scholar]
- 7.Ng W.L., Lim K.S., Hariraj V., et al. Incidence of allopurinol-induced severe cutaneous adverse drug reaction in Malaysia. Br. J. Clin. Pharmacol. 2022;88(8):3782–3788. doi: 10.1111/bcp.15327. [DOI] [PubMed] [Google Scholar]
- 8.Li Y., Lin Z., Wang Y., Wu H., Zhang B. Are hyperuricemia and gout different diseases? Comment on the guidelines for the diagnosis and management of hyperuricemia and gout with the healthcare professional perspectives in China. Int J Rheum Dis. 2023;26(9):1866–1868. doi: 10.1111/1756-185X.14592. [DOI] [PubMed] [Google Scholar]
- 9.Maruhashi T., Hisatome I., Kihara Y., Higashi Y. Hyperuricemia and endothelial function: from molecular background to clinical perspectives. Atherosclerosis. 2018;278:226–231. doi: 10.1016/j.atherosclerosis.2018.10.007. [DOI] [PubMed] [Google Scholar]
- 10.Miranda-Aquino T., Pérez-Topete S.E., González-Padilla C., et al. Asymptomatic hyperuricaemia and coronary artery disease. Reumatol Clin (Engl Ed). 2021;17(5):263–267. doi: 10.1016/j.reuma.2019.08.003. [DOI] [PubMed] [Google Scholar]
- 11.Agnoletti D., Cicero A.F.G., Borghi C. The impact of uric acid and hyperuricemia on cardiovascular and renal systems. Cardiol. Clin. 2021;39(3):365–376. doi: 10.1016/j.ccl.2021.04.009. [DOI] [PubMed] [Google Scholar]
- 12.Yanai H., Adachi H., Hakoshima M., Katsuyama H. Molecular biological and clinical understanding of the pathophysiology and treatments of hyperuricemia and its association with metabolic syndrome, cardiovascular diseases and chronic kidney disease. Int. J. Mol. Sci. 2021;22(17):9221. doi: 10.3390/ijms22179221. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13.Ohsawa I., Ishikawa M., Takahashi K., et al. Hydrogen acts as a therapeutic antioxidant by selectively reducing cytotoxic oxygen radicals. Nat. Med. 2007;13(6):688–694. doi: 10.1038/nm1577. [DOI] [PubMed] [Google Scholar]
- 14.Liu B., Lv P., Zhang X., et al. Zn-Fe primary battery-enabled controlled hydrogen release in stomach for improving insulin resistance in obesity-associated type 2 diabetes. Bioact. Mater. 2024;33:242–250. doi: 10.1016/j.bioactmat.2023.11.003. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15.Liu B., Zhao M., Xue J., Gu Q., Zhang X., Qin S. Hydrogen influences HDL-associated enzymes and reduces oxidized phospholipids levels in rats fed with a high-fat diet. Life Sci. 2021;267 doi: 10.1016/j.lfs.2020.118945. [DOI] [PubMed] [Google Scholar]
- 16.Liu B.Y., Xue J.L., Gu Q.Q., et al. In vivo microelectrode monitoring of real-time hydrogen concentration in different tissues of rats after inhaling hydrogen gas. Med. Gas Res. 2022;12(3):107–112. doi: 10.4103/2045-9912.330694. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17.Si Y., Tian H., Dong B., et al. Effects of hydrogen as adjuvant treatment for unstable angina. Exp. Biol. Med. 2021;246(18):1981–1989. doi: 10.1177/15353702211009138. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18.Qin S. Role of hydrogen in atherosclerotic disease: from bench to bedside. Curr. Pharmaceut. Des. 2021;27(5):713–722. doi: 10.2174/1381612826666201124112152. [DOI] [PubMed] [Google Scholar]
- 19.Kura B., Szantova M., LeBaron T.W., et al. Biological effects of hydrogen water on subjects with nafld: a randomized, placebo-controlled trial. Antioxidants. 2022;11(10):1935. doi: 10.3390/antiox11101935. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20.Liang B., Shi L., Du D., et al. Hydrogen-rich water ameliorates metabolic disorder via modifying gut microbiota in impaired fasting glucose patients: a randomized controlled study. Antioxidants. 2023;12(6):1245. doi: 10.3390/antiox12061245. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 21.Xue J., Zhao M., Liu Y., et al. Hydrogen inhalation ameliorates hepatic inflammation and modulates gut microbiota in rats with high-fat diet-induced non-alcoholic fatty liver disease. Eur. J. Pharmacol. 2023;947 doi: 10.1016/j.ejphar.2023.175698. [DOI] [PubMed] [Google Scholar]
- 22.Liu B., Xie Y., Chen J., et al. Protective effect of molecular hydrogen following different routes of administration on D-galactose-induced aging mice. J. Inflamm. Res. 2021;14:5541–5550. doi: 10.2147/JIR.S332286. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 23.Zheng Y., Han C., Chen Z., Zeng Q. A study on the effect of hydrogen on the hyperuricemia in males. Chin. J. Clin. Hepatol. 2017;20(2):118–121. (In Chinese) [Google Scholar]
- 24.Sun Y., Sun J., Zhang P., Zhong F., Cai J., Ma A. Association of dietary fiber intake with hyperuricemia in U.S. adults. Food Funct. 2019;10(8):4932–4940. doi: 10.1039/c8fo01917g. [DOI] [PubMed] [Google Scholar]
- 25.Li J.Y., Lee J.I., Lu C.C., et al. Hyperuricemia and its association with osteoporosis in a large asian cohort. Nutrients. 2022;14(11):2206. doi: 10.3390/nu14112206. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 26.Bulut M., Çelebi Sezer Y., Ceylan M.M., Alwazeer D., Koyuncu M. Hydrogen-rich water can reduce the formation of biogenic amines in butter. Food Chem. 2022;384 doi: 10.1016/j.foodchem.2022.132613. [DOI] [PubMed] [Google Scholar]
- 27.Cole A.R., Sperotto F., DiNardo J.A., et al. Safety of prolonged inhalation of hydrogen gas in air in healthy adults. Crit Care Explor. 2021;3(10):e543. doi: 10.1097/CCE.0000000000000543. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 28.Kajiyama S., Hasegawa G., Asano M., et al. Supplementation of hydrogen-rich water improves lipid and glucose metabolism in patients with type 2 diabetes or impaired glucose tolerance. Nutr. Res. 2008;28(3):137–143. doi: 10.1016/j.nutres.2008.01.008. [DOI] [PubMed] [Google Scholar]
- 29.Song G., Li M., Sang H., et al. Hydrogen-rich water decreases serum LDL-cholesterol levels and improves HDL function in patients with potential metabolic syndrome. J. Lipid Res. Jul 2013;54(7):1884–1893. doi: 10.1194/jlr.M036640. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 30.Xie F., Jiang X., Yi Y., et al. Different effects of hydrogen-rich water intake and hydrogen gas inhalation on gut microbiome and plasma metabolites of rats in health status. Sci. Rep. 2022;12(1):7231. doi: 10.1038/s41598-022-11091-1. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 31.Singh R.B., Halabi G., Fatima G., Rai R.H., Tarnava A.T., LeBaron T.W. Molecular hydrogen as an adjuvant therapy may be associated with increased oxygen saturation and improved exercise tolerance in a COVID-19 patient. Clin Case Rep. 2021;9(11) doi: 10.1002/ccr3.5039. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 32.Nakao A., Toyoda Y., Sharma P., Evans M., Guthrie N. Effectiveness of hydrogen rich water on antioxidant status of subjects with potential metabolic syndrome-an open label pilot study. J. Clin. Biochem. Nutr. 2010;46(2):140–149. doi: 10.3164/jcbn.09-100. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 33.LeBaron T.W., Singh R.B., Fatima G., et al. The effects of 24-week, high-concentration hydrogen-rich water on body composition, blood lipid profiles and inflammation biomarkers in men and women with metabolic syndrome: a randomized controlled trial. Diabetes Metab Syndr Obes. 2020;13:889–896. doi: 10.2147/DMSO.S240122. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 34.Korovljev D., Stajer V., Ostojic J., LeBaron T.W., Ostojic S.M. Hydrogen-rich water reduces liver fat accumulation and improves liver enzyme profiles in patients with non-alcoholic fatty liver disease: a randomized controlled pilot trial. Clin Res Hepatol Gastroenterol. 2019;43(6):688–693. doi: 10.1016/j.clinre.2019.03.008. [DOI] [PubMed] [Google Scholar]
- 35.Sumbalová Z., Kucharská J., Rausová Z., et al. The effect of adjuvant therapy with molecular hydrogen on endogenous coenzyme Q(10) levels and platelet mitochondrial bioenergetics in patients with non-alcoholic fatty liver disease. Int. J. Mol. Sci. 2023;24(15) doi: 10.3390/ijms241512477. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 36.Luis-Rodríguez D., Donate-Correa J., Martín-Núñez E., et al. Serum urate is related to subclinical inflammation in asymptomatic hyperuricaemia. Rheumatology. 2021;60(1):371–379. doi: 10.1093/rheumatology/keaa425. [DOI] [PubMed] [Google Scholar]
- 37.Copur S., Demiray A., Kanbay M. Uric acid in metabolic syndrome: does uric acid have a definitive role? Eur. J. Intern. Med. 2022;103:4–12. doi: 10.1016/j.ejim.2022.04.022. [DOI] [PubMed] [Google Scholar]
- 38.Liu N., Xu H., Sun Q., et al. The role of oxidative stress in hyperuricemia and xanthine oxidoreductase (XOR) inhibitors. Oxid. Med. Cell. Longev. 2021;2021 doi: 10.1155/2021/1470380. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 39.Furuhashi M. New insights into purine metabolism in metabolic diseases: role of xanthine oxidoreductase activity. Am. J. Physiol. Endocrinol. Metab. 2020;319(5):E827–e834. doi: 10.1152/ajpendo.00378.2020. [DOI] [PubMed] [Google Scholar]
- 40.Battelli M.G., Bortolotti M., Polito L., et al. The role of xanthine oxidoreductase and uric acid in metabolic syndrome. Biochim. Biophys. Acta, Mol. Basis Dis. 2018;1864(8):2557–2565. doi: 10.1016/j.bbadis.2018.05.003. [DOI] [PubMed] [Google Scholar]
- 41.Battelli M.G., Polito L., Bolognesi A. Xanthine oxidoreductase in atherosclerosis pathogenesis: not only oxidative stress. Atherosclerosis. 2014;237(2):562–567. doi: 10.1016/j.atherosclerosis.2014.10.006. [DOI] [PubMed] [Google Scholar]
- 42.Jin Z., Zhao P., Gong W., et al. Fe-porphyrin: a redox-related biosensor of hydrogen molecule. Nano Res. 2023;16(2):2020–2025. [Google Scholar]
- 43.Tao G., Zhang G., Chen W., et al. A randomized, placebo-controlled clinical trial of hydrogen/oxygen inhalation for non-alcoholic fatty liver disease. J. Cell Mol. Med. 2022;26(14):4113–4123. doi: 10.1111/jcmm.17456. [DOI] [PMC free article] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Supplementary Materials
Data Availability Statement
The data that support the findings of this study are available from the corresponding author upon reasonable request.